ProQR Raises $55.8M in Public Offering and Private Placement, Eli Lilly Maintains Stake
Summary
ProQR Therapeutics successfully raised $55.8 million through a public offering and a concurrent private placement to Eli Lilly, securing vital funding for its pipeline development despite significant dilution.
Key Events
-
Capital Raise Finalized
ProQR completed a public offering of 27,624,310 ordinary shares at $1.81 per share, raising $50.0 million gross, and a concurrent private placement of 5,100,780 shares to Eli Lilly and Company at the same price. The total net proceeds are approximately $55.8 million.
-
Significant Dilution
The offering and private placement will result in the issuance of 32,725,090 new shares, representing approximately 30.2% dilution to existing shareholders based on shares outstanding as of June 23, 2026.
-
Strategic Partner Participation
Eli Lilly and Company, an existing strategic partner, participated in a concurrent private placement to maintain its pro-rata beneficial ownership, signaling continued confidence in ProQR.
-
Funding for Pipeline Development
Net proceeds will primarily fund research and clinical development of current or additional pipeline candidates, as well as for working capital, capital expenditures, and other general corporate purposes.
Analysis
This substantial capital raise provides critical funding for ProQR's research and clinical development pipeline, extending its operational runway. The offering was priced at the market's close on June 24, 2026, at $1.81 per share, which is now a premium to the current market price of $1.50. The inclusion of a significant concurrent private placement to strategic partner Eli Lilly and Company, who is maintaining its pro-rata ownership, demonstrates strong institutional confidence, especially following recent positive Phase 1 clinical data for AX-0810. While highly dilutive for existing shareholders, securing this financing is crucial for a clinical-stage biotechnology company to advance its programs.
At the time of this filing, PRQR was trading at $1.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $164.9M. The 52-week trading range was $1.33 to $3.10. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.